Antifungal, Antiviral, and Antiparasitic Agents
This area covers the pharmacology of anti-infective agents directed against pathogens other than bacteria: fungi, viruses, and parasites. Unlike antibacterials, these drugs must act against targets that are either eukaryotic (and therefore biochemically close to human cells) or wholly dependent on host-cell machinery (viruses), which makes achieving selective toxicity the central pharmacological challenge of the field.
Definition
Antifungal, antiviral, and antiparasitic agents are anti-infective drugs whose targets reside in fungal, viral, or parasitic pathogens, exploiting biochemical differences (or pathogen-specific enzymes) between pathogen and host to obtain selective toxicity.
Scope
The area groups antifungal, antiviral, and antiparasitic chemotherapy as a reference cluster within chemotherapy and antimicrobials. It orients the reader to the major drug classes, their molecular targets, and the resistance problems that distinguish anti-eukaryote and antiviral therapy from antibacterial therapy. Detailed treatment of classes, mechanisms, and resistance is delegated to the four topic nodes beneath it. It is educational reference material, not clinical guidance.
Sub-topics
Core questions
- Why is selective toxicity harder to achieve against fungi, viruses, and parasites than against bacteria?
- What pathogen-specific targets do the major drug classes exploit?
- How does drug resistance arise differently in eukaryotic pathogens and in viruses?
Key concepts
- Selective toxicity against eukaryotic and viral targets
- Ergosterol and the fungal cell as drug targets
- Nucleoside analogs and virus-encoded enzymes
- Pathogen-specific metabolic pathways (e.g., parasite heme and folate metabolism)
- Static versus cidal activity
- Drug resistance in eukaryotic pathogens and viruses
- Latency and host-dependence as barriers to cure
Mechanisms
Because fungi and parasites are eukaryotes, drugs against them must target features that differ from the host: the fungal-specific sterol ergosterol and the fungal cell wall, or parasite-specific pathways such as heme detoxification and folate synthesis. Antivirals face the opposite problem, since viruses have few targets of their own, so most exploit virus-encoded enzymes (polymerases, proteases, neuraminidase) or virus-specific steps in the replication cycle, with nucleoside and nucleotide analogs a recurring strategy. Across all three pathogen groups, the narrow target space and the genetic adaptability of pathogens make resistance a defining concern.
Clinical relevance
These agents underpin the management of invasive fungal disease, viral infections such as HIV and hepatitis, and parasitic diseases including malaria and helminth infections, which together impose a large global health burden. The area explains how such drugs are classified and how they work as background for evidence appraisal; it does not provide dosing or individualized treatment recommendations.
Epidemiology
Invasive fungal infections cause substantial mortality, particularly in immunocompromised patients, and have been described as an underrecognized global health problem. Malaria and soil-transmitted helminth infections remain among the most prevalent parasitic diseases worldwide, and chronic viral infections affect very large populations, together shaping the demand for these drug classes.
History
Effective non-antibacterial chemotherapy developed largely in the second half of the twentieth century: polyene and azole antifungals, the first nucleoside-analog antivirals, and the displacement of older antimalarials by artemisinin-based therapy. The arrival of combination antiretroviral therapy and direct-acting antivirals later transformed the antiviral field, while echinocandins and newer azoles expanded antifungal options.
Related topics
Seminal works
- deClercq-2016
- roemer-2014
- white-2014
- brown-2012
Frequently asked questions
- Why are antifungal and antiparasitic drugs harder to design than antibacterials?
- Fungi and parasites are eukaryotes, so they share much of their biochemistry with human cells; drugs must target the few features that differ, which narrows the available targets and raises the risk of host toxicity.
- What unites these three drug groups into one area?
- All three act against non-bacterial pathogens and share the central problem of achieving selective toxicity against targets that are either eukaryotic or dependent on host-cell machinery.